Skyrizi Risankizumab Crohns Disease Ulcerative Colitis IBD 2026
Author: Critical Kare PharmaIBD & Advanced Biologics Desk
On November 14, 2026, European and North American gastroenterology congresses highlighted the established therapeutic supremacy of Skyrizi® (Risankizumab-rzaa 600 mg IV vial and 180 mg/360 mg on-body subcutaneous injectors) by AbbVie across both Crohn's disease and ulcerative colitis.
By exclusively targeting the p19 subunit of interleukin-23 with high affinity, Skyrizi achieves profound endoscopic healing and long-term histological-endoscopic mucosal remission while demonstrating an exemplary infection safety profile compared to older anti-TNF and JAK inhibitor classes.
Through Critical Kare Pharma, authentic manufacturer packs of Skyrizi Risankizumab IV and On-Body Subcutaneous Injectors are delivered worldwide under 2°C–8°C cold-chain surveillance.
Landmark ADVANCE, MOTIVATE & COMMAND Trial Data
- Endoscopic Response in Crohn's Disease: Over 40% of patients achieved endoscopic response at Week 12 following three 600 mg IV induction doses, maintaining steroid-free clinical remission through 52 weeks on 360 mg subcutaneous on-body delivery every 8 weeks.
- Ulcerative Colitis Success: In the COMMAND maintenance trial, 31% of risankizumab-treated UC patients achieved complete clinical remission and 40% attained endoscopic improvement at one year.
- Histological Healing: High rates of complete crypt architecture restoration and mucosal healing, translating to reduced hospitalizations and bowel resection surgeries.
Targeted IL-23p19 Pharmacology
Risankizumab blocks IL-23 without cross-reacting with IL-12, thereby extinguishing the chronic pathogenic IL-17/IL-22 inflammatory axis driven by Th17 lymphocytes without impairing Th1-mediated antimicrobial surveillance. This selective mechanism explains why opportunistic infection rates remain near background placebo levels.
International Sourcing & Logistics
Critical Kare Pharma ensures temperature-validated transport from Europe and North America directly to gastroenterology hospitals, infusion suites, and named patients globally.



